A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours,
to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or
recommended phase II dose (RP2D) of SHR-A1921